2023 World Conference on Lung Cancer (Posters)-P1.25. Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study)

P1.25. Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study) - PDF(Abstract)

Back to course

Pdf Summary

The study presented at the WCLC 2023 conference aimed to investigate the prognosis and post-relapse treatment of patients with completely resected lung adenocarcinoma harboring common EGFR mutation in Japan. The researchers conducted a multicenter retrospective observational study at 21 centers in Japan, involving 1435 patients who underwent complete resection for lung adenocarcinoma between 2015-18.<br /><br />The results showed that adjuvant chemotherapy did not significantly improve prognosis at any pathological stage. However, postoperative adjuvant therapy with osimertinib was identified as a promising treatment strategy for these patients. Interestingly, the study found that osimertinib for post-relapse first-line therapy did not significantly prolong post-relapse overall survival compared to 1st - 2nd generation TKIs (tyrosine kinase inhibitors). Treatment-related pneumonitis was observed to be slightly more common in osimertinib treatment compared to other generation TKIs. It was also found that CNS metastasis did not adversely affect the performance status at relapse, suggesting that it may not have a negative impact on post-relapse treatment.<br /><br />The researchers concluded that adjuvant chemotherapy may not significantly improve prognosis for patients with lung adenocarcinoma harboring common EGFR mutation. Osimertinib as postoperative adjuvant therapy shows promise but may not significantly prolong post-relapse overall survival compared to other generation TKIs. The study highlighted the importance of long-term prospective observational studies to further investigate the efficacy and safety of osimertinib as postoperative adjuvant therapy in real-world settings.<br /><br />Keywords: EGFR, real world data, osimertinib.

Asset Subtitle

Shinya Katsumata

Meta Tag

Speaker Shinya Katsumata

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

WCLC 2023 conference

prognosis

post-relapse treatment

lung adenocarcinoma

EGFR mutation

osimertinib

adjuvant therapy

retrospective study

tyrosine kinase inhibitors

real-world settings